Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMathilde Poplineau

Discussion

Loading...

Member takes

Overview

Findings reveal low EZH2 levels worsen outcomes in acute myelogenous leukemia, suggesting pathways for targeted therapies.

Key Points

  • This research investigates the prognostic significance of EZH2 levels in acute myelogenous leukemia (AML) patients.
  • Measured EZH2 and other proteins using Reverse Phase Protein Arrays in 806 AML samples.
  • Analyzed mutation status and treatment data from 529 patients with EZH2 mutations and wild-type cases.
  • Employed statistical tests including LogRank and Cox proportional hazards models to assess correlations and outcomes.
  • 95% of AML cases exhibited low EZH2 protein levels compared to normal controls.
  • Low EZH2 levels were associated with older age and unfavorable cytogenetics.
  • Overall Survival was similar for EZH2 mutation and low EZH2 wild-type cases, indicating poor prognosis.

Cite This Study

Mathilde Poplineau (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e046https://doi.org/10.1182/blood-2025-5259
View Full Paper
Ask AI
Bookmark
Share